Igor Pasyura

Learn More
OBJECTIVE To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on MRI lesion activity and load, atrophy, and magnetization transfer ratio (MTR) measures from the Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (CONFIRM) study. METHODS CONFIRM was a 2-year, placebo-controlled(More)
Cranio-cerebral trauma is considered as one of the leading causes of mortality, long-term temporary incapacity for work and disability. The aim of the article is to study distant consequences of the so-called "combat cranio-cerebral injury". 108 male patients - participants of the military actions in Afghanistan were examined. The patients were divided(More)
Background: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsingremitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuroprotective effects. In clinical trials,DMFwasassociatedwith reduced white blood cell and absolute lymphocyte counts. CurrentUSprescribing(More)
  • 1